SWTX
Income statement / Annual
Last year (2024), SpringWorks Therapeutics, Inc.'s total revenue was $191.59 M,
an increase of 3,417.33% from the previous year.
In 2024, SpringWorks Therapeutics, Inc.'s net income was -$258.13 M.
See SpringWorks Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$191.59 M |
$5.45 M |
$6.15 M |
$0.00 |
$35.00 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$12.55 M
|
$422.00 K
|
$1.90 M
|
$490.00 K
|
$349.00 K
|
$192.00 K
|
$17.33 K
|
$3.18 K
|
| Gross Profit |
$179.04 M
|
$5.03 M
|
$4.25 M
|
-$490.00 K
|
$34.65 M
|
-$192.00 K
|
-$17.33 K
|
-$3.18 K
|
| Gross Profit Ratio |
0.93
|
0.92
|
0.69
|
0
|
0.99
|
0
|
0
|
0
|
| Research and Development Expenses |
$200.52 M
|
$150.49 M
|
$146.12 M
|
$101.68 M
|
$51.86 M
|
$42.55 M
|
$9.90 M
|
$2.80 M
|
| General & Administrative Expenses |
$256.65 M
|
$197.55 M
|
$134.55 M
|
$71.79 M
|
$29.47 M
|
$16.69 M
|
$8.59 M
|
$5.58 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$3.73 M
|
| Selling, General & Administrative Expenses |
$256.65 M
|
$197.55 M
|
$134.55 M
|
$71.79 M
|
$29.47 M
|
$16.69 M
|
$8.59 M
|
$1.86 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$1.90 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$457.17 M
|
$348.04 M
|
$278.78 M
|
$173.47 M
|
$81.32 M
|
$59.24 M
|
$18.49 M
|
$4.66 M
|
| Cost And Expenses |
$469.72 M
|
$348.46 M
|
$280.67 M
|
$173.47 M
|
$81.32 M
|
$59.24 M
|
$18.49 M
|
$4.66 M
|
| Interest Income |
$26.00 M
|
$22.95 M
|
$6.15 M
|
$698.00 K
|
$1.33 M
|
$3.55 M
|
$678.00 K
|
$63.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.47 M
|
$1.67 M
|
$1.90 M
|
$490.00 K
|
$349.00 K
|
$192.00 K
|
$17.33 K
|
$3.18 K
|
| EBITDA |
-$274.66 M |
-$341.35 M |
-$275.52 M |
-$172.98 M |
-$45.98 M |
-$59.05 M |
-$18.47 M |
-$4.64 M |
| EBITDA Ratio |
-1.43
|
-62.67
|
-44.82
|
0
|
-1.31
|
0
|
0
|
0
|
| Operating Income Ratio |
-1.45
|
-62.97
|
-45.66
|
0
|
-1.32
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$20.00 M
|
$17.91 M
|
$3.26 M
|
-$442.00 K
|
$750.00 K
|
$933.00 K
|
$678.00 K
|
$21.00 K
|
| Income Before Tax |
-$258.13 M
|
-$325.10 M
|
-$277.42 M
|
-$173.91 M
|
-$45.57 M
|
-$58.31 M
|
-$17.81 M
|
-$4.64 M
|
| Income Before Tax Ratio |
-1.35
|
-59.68
|
-45.13
|
0
|
-1.3
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.00
|
| Net Income |
-$258.13 M
|
-$325.10 M
|
-$277.42 M
|
-$173.21 M
|
-$45.57 M
|
-$58.31 M
|
-$17.81 M
|
-$4.64 M
|
| Net Income Ratio |
-1.35
|
-59.68
|
-45.13
|
0
|
-1.3
|
0
|
0
|
0
|
| EPS |
-3.48 |
-5.15 |
-5.21 |
-3.59 |
-1.05 |
-1.27 |
-0.8 |
-0.11 |
| EPS Diluted |
-3.48 |
-5.15 |
-5.21 |
-3.59 |
-1.05 |
-1.27 |
-0.8 |
-0.11 |
| Weighted Average Shares Out |
$74.13 M
|
$63.12 M
|
$53.29 M
|
$48.50 M
|
$43.30 M
|
$43.01 M
|
$22.20 M
|
$43.23 M
|
| Weighted Average Shares Out Diluted |
$74.13 M
|
$63.12 M
|
$53.29 M
|
$48.50 M
|
$43.30 M
|
$43.01 M
|
$22.20 M
|
$43.23 M
|
| Link |
|
|
|
|
|
|
|
|
